{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:44:08Z","timestamp":1789602248663,"version":"build-2803163510"},"reference-count":18,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Novel targeted agents have transformed the treatment of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL), including continuous BTK inhibitor (BTKi) therapy and time\u2010limited regimens such as venetoclax\u2010obinutuzumab (Ven\u2010O) and ibrutinib\u2010venetoclax (I\u2009+\u2009V). However, factors guiding first\u2010line treatment decisions in routine practice remain poorly defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe real\u2010world first\u2010line treatment patterns and identify factors associated with therapy selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, population\u2010based study included consecutive patients initiating first\u2010line therapy for CLL\/SLL in 2024 in Alberta, Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 148 patients with median age 71\u2009years, time\u2010limited targeted therapy was selected for 75 (51%), including Ven\u2010O (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200973) and I\u2009+\u2009V (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092). Continuous BTKi therapy was used in 65 (44%), while chemotherapy\u2010based regimens were uncommon (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098, 5%). Among 138 patients treated with either continuous BTKi or Ven\u2010O, BTKi use was significantly more frequent among those with del(17p)\/\n                      <jats:italic>TP53<\/jats:italic>\n                      mutation (84% vs. 16%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0002), age &gt;\u200975\u2009years (66% vs. 34%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0051), and residence &gt;\u2009100\u2009km from an obinutuzumab\u2010initiating cancer center (70% vs. 30%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.031).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Time\u2010limited and continuous targeted therapies are used with similar frequency for CLL\/SLL, with selection shaped by age,\n                      <jats:italic>TP53<\/jats:italic>\n                      aberrations, geography, and patient preferences. These findings highlight the importance of personalized care and the need to reduce access barriers to time\u2010limited strategies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.70137","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:35:21Z","timestamp":1771288521000},"page":"845-849","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real\u2010World Selection of Venetoclax\u2010Obinutuzumab Versus\n                    <scp>BTK<\/scp>\n                    Inhibitor Therapy for Treatment\u2010Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma"],"prefix":"10.1111","volume":"116","author":[{"given":"Rebecca","family":"Tidswell","sequence":"first","affiliation":[{"name":"Arthur Child Comprehensive Cancer Centre  Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-1708","authenticated-orcid":false,"given":"Carolyn","family":"Owen","sequence":"additional","affiliation":[{"name":"Arthur Child Comprehensive Cancer Centre  Calgary Canada"},{"name":"University of Calgary  Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Shafey","sequence":"additional","affiliation":[{"name":"Arthur Child Comprehensive Cancer Centre  Calgary Canada"},{"name":"University of Calgary  Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Perry","sequence":"additional","affiliation":[{"name":"Arthur Child Comprehensive Cancer Centre  Calgary Canada"},{"name":"University of Calgary  Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanette","family":"Cox\u2010Kennett","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute  Edmonton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Sterrett","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute  Edmonton Canada"},{"name":"University of Alberta  Edmonton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthea","family":"Peters","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute  Edmonton Canada"},{"name":"University of Alberta  Edmonton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8918-6598","authenticated-orcid":false,"given":"Robert","family":"Puckrin","sequence":"additional","affiliation":[{"name":"Arthur Child Comprehensive Cancer Centre  Calgary Canada"},{"name":"University of Calgary  Calgary Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024028205"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024476"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02265"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024631"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00196-7"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00452-7"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70093_71"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200701"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2521656"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050799"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.888"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2374040"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2515458"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70100"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.016"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2005943"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181661"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020158"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70137","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70137","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:04:31Z","timestamp":1777982671000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/ejh.70137"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70137","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"2025-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}